Cargando…
MIS-C Treatment: Is IVIG Always Necessary?
Background: MIS-C is a potentially severe inflammatory syndrome associated with SARS-CoV-2 exposure. Intravenous immunoglobulin (IVIG) is considered the first-tier therapy, but it implies infusion of large fluid volumes that may worsen cardiac function. Patients and Methods: Since April 2020, we hav...
Autores principales: | Licciardi, Francesco, Baldini, Letizia, Dellepiane, Marta, Covizzi, Carlotta, Mogni, Roberta, Pruccoli, Giulia, Orsi, Cecilia, Rabbone, Ivana, Parodi, Emilia, Mignone, Federica, Montin, Davide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595395/ https://www.ncbi.nlm.nih.gov/pubmed/34805048 http://dx.doi.org/10.3389/fped.2021.753123 |
Ejemplares similares
-
Corrigendum: MIS-C Treatment: Is IVIG Always Necessary?
por: Licciardi, Francesco, et al.
Publicado: (2022) -
Outcomes of MIS-C patients treated with anakinra: a retrospective multicenter national study
por: Licciardi, Francesco, et al.
Publicado: (2023) -
Discordance between Clinical and Ultrasound Examinations in Juvenile Idiopathic Arthritis: An Experimental Approach
por: Licciardi, Francesco, et al.
Publicado: (2022) -
Unraveling the mechanisms of IVIG immunotherapy in MIS-C
por: Ganigara, Madhusudan, et al.
Publicado: (2021) -
Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics
por: DeBiasi, Roberta L.
Publicado: (2021)